- French biotech company will use its bioSens-AllTM proprietary technology to correlate impact of GPCR mutations on signaling pathways
- Results may constitute guidance for…
Continue Reading
News
Domain Therapeutics enters into a new collaboration agreement with Pfizer Inc. to profile signaling pathways of GPCRs across multiple diseases
Domain Therapeutics signs a multi-target research collaboration and license agreement with Boehringer Ingelheim on G Protein-Coupled Receptors (GPCRs) for Central Nervous System Disorders.
Domain Therapeutics’ unique platform technologies will be used to identify novel treatment approaches for neuropsychiatric diseases.
Strasbourg, France, December 4, 2018 – Domain Therapeutics announces a multi-target…
Continue ReadingIn Vitro Pharmacological Characterization of Buprenorphine, Samidorphan, and Combinations Being Developed as an Adjunctive Treatment for Major Depressive Disorder
Jean M. Bidblack, Brian I. Knapp, Daniel R. Deaver, Margarita Plotnikava, Derrick Arnelle, Angela M. Wonsey, May Fern Toh, Sokhom S. Pin, and Mark N. Namchuk
Domain Therapeutics octroie à Bristol-Myers Squibb une licence non exclusive sur la technologie bioSens-All™ dédiée aux récepteurs couplés aux protéines G
La technologie donne accès à une nouvelle génération de biosenseurs visant à optimiser la découverte de médicaments
Strasbourg, France, le 27 février 2018 – Domain Therapeutics, une société biopharmaceutique…
Continue ReadingDomain Therapeutics grants Bristol-Myers Squibb non-exclusive license for G protein-coupled receptor bioSens-All™ technology
Technology provides access to new generation of sensitive biosensors to enhance drug discovery
Strasbourg, France, February 27, 2018 – Domain Therapeutics, a France- and Quebec-based biopharmaceutical company that specializes in the…
Continue ReadingPfizer Inc. and Domain Therapeutics enter into a collaboration agreement on bioSensAll™
Proprietary technology will be used to profile signaling of mutant GPCRs in order to improve and accelerate the validation of novel GPCR drug targets
Strasbourg, France, and Montreal,…
Continue ReadingDT signs GPCR licensing agreement with Alkermes.
Domain Therapeutics grants Alkermes a non-exclusive license for its G Protein-Coupled Receptor bioSensAll™ technology. Technology provides access to a new set of sensitive biosensors that will facilitate drug…
Continue ReadingDT, Université de Montréal, IRICoR and McGill University extend licensing and partnership agreement on G Protein-Coupled Receptor biosensor technology.
Domain Therapeutics will get exclusive access to a new set of more powerful biosensors that will facilitate profiling of more effective and safer drug candidates.
Domain Therapeutics, a France…
Continue ReadingDT opens a North American subsidiary at Montreal’s NEOMED Institute.
Canada-based Domain Therapeutics NA Inc. will focus exclusively on leveraging the BioSens-All(TM) technology.
Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting…
Continue ReadingDT, Université de Montréal, IRICoR and McGill University sign new licensing and partnership agreement on G-Protein Coupled Receptor biosensor technology.
Domain Therapeutics, a France-based biopharmaceutical company that specializes in the research and development of new drug candidates that target G-protein coupled receptors (GPCRs), is pleased to announce the…
Continue Reading